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Abstract: The scope and ambitions of biomedical institutions worldwide currently working toward
the integration of personalized medicine (PM) require recognizing the potential profound impact
on regulatory standards and on the economic functioning and financing of healthcare. Against this
background, researchers and policymakers must manage the arising challenges for the healthcare
systems. In this paper we study the literature related to the consequences of PM on health insurance
and care systems. Using the PRISMA research protocol, we search the existing body of literature
and analyze publications dealing with insurance (419 papers) in the field of PM. After a detailed
reading of the 52 studies included in our analysis, we synthesize challenges in three fields that must
be addressed to avoid hindering the implantation of PM. The key issues that we highlight concern
(1) a lack of clear and consistent data on the economic relevance of PM, (2) a value-oriented and
cost-efficient definition of reimbursement thresholds, (3) the implementation of PM in the prevailing
healthcare system. In the meantime, we provide several solutions to these concerns; we present
(a) risk-sharing contracts that can deal with the emerging coverage challenges, (b) criteria that could
constitute future reimbursement thresholds and (c) examples of successful implementations of PM
into healthcare systems. Our findings are relevant for policymakers and health insurance companies
for redefining the guidelines for the healthcare schemes of the future.
Keywords: personalized medicine; health insurance; financial management; genetics
1. Introduction
Personalized, stratified, precision or genomic medicine bear the same logic: a particular problem
requires a tailored solution, i.e., a specific genetic mutation leading to a health condition should
be treated with a specific drug. The often costly trial-to-error paradigm leading to adverse drug
responses (Spear et al. 2001; Sultana et al. 2013) is being slowly replaced by a data-based optimization
of resources that we refer to with personalized medicine (PM). In the prevailing procedures, the time,
health and energy wasted as well by doctors as by patients in an iterative search of the best drug
response translates into expenses paid by the sponsors, i.e., insurers, governments or private payers.
Fast forward twenty years, with PM, before a patient starts his/her course of treatment, we determine
which drug will lead to the best outcome and minimize the risks of adverse events. Doctors have access
to the necessary medical data of the patient on the spot with the implementation of electronic health
records (Henry et al. 2016). Individuals have the possibility of having their DNA sequenced to draw a
risk profile for the most common afflictions as well as personal at-risk conditions (Hammond 2020).
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Finally, combining all the flows of health-related data (such as information collected from wearable
devices) with gene mutations, research hubs gain a more precise and accurate knowledge, which is
clinically applied. Going back to the present, we already have the technology for a fast, cheap and
accurate DNA sequencing. For instance, next generation sequencing technology (NGS) has replaced
the Sanger method, resulting in the cost of a whole genome sequencing drastically decreased with a
cutback in prices by two hundred times in only ten years, decreasing from roughly USD 200,000 in 2009
to less than USD 1000 in May 2020 (National Human Genome Research Institute 2020). Smart wearable
devices are continuously collecting data (Dunn et al. 2018) laying the ground for a common database
that will consolidate genetic, metabolic and lifestyle data. Now, for clinical integration of PM to
become reality, the most important hurdle is not of scientific nature but rather economic and behavioral
or systemic.
Payers, i.e., governments, insurers and patients, are key to completely unlock PM’s systematic use
in the healthcare system. Financial cover for personalized drugs and genetic sequencing is, nonetheless,
yet unestablished with the institutional payers that are in the scope of our study. Such payers are
typically the government when regarding health insurance in terms of social insurance or the private
insurers when looking at private health insurance coverage. Today, most often we lack commonly
accepted figures on clinical utility and cost-efficiency of PM. This renders insurers rather skeptical
(Cohen et al. 2013; Trosman et al. 2015; Messner et al. 2016) and keeping policymakers from listing
such drugs and treatments in the catalog of what social security and social health insurance cover.
Additionally, as we are still in the infancy of PM, payers must invest in the short term but the benefits
are to be reaped in the long run. This is especially critical in (private) insurance contracts where patients
can switch their insurance provider and thus deter companies to consider longer terms. To counter the
paucity of cost-efficiency evidence, “first-mover” payers are needed to cover the treatments and to
generate enough data. Thereby, governments and pharmaceutical companies may play an important
role since private insurers tend to selectively only cover proven drugs. Indeed, one key challenge is to
provide a means to generate data and knowledge while limiting costs.
In this systematic literature review, we analyze the different challenges for integrating PM
into healthcare systems from the payers’ perspective. The viewpoint and the obstacles that payers
stumble upon when it comes to financing PM have seldom been investigated. This paper fills this
gap and gathers the extant body of knowledge. After a presentation of the methodology used for
selecting articles in Section 2, the remainder of this paper logically follows the challenges faced by
the payers when assessing PM. In Section 3, we document the economic relevance of PM with an
emphasis on the lack of evidence and the potential remedies to the issue. In Section 4, we expose the
governance challenges that impede PM coverage with a selection of possible solutions to tackle them.
Finally, in Section 5, we develop on what characteristics slow down the integration of PM into the
healthcare system and how to overcome them. We conclude the paper with a discussion in Section 6.
In Appendix A we provide a comprehensive synopsis of the reviewed papers.
2. Methodology
2.1. Review Strategy
To conduct our literature review, we use the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) protocol (Moher et al. 2015). To build the initial catalog of publications for
review, we search the Web of Science Core Collection database.1 The extraction of bibliography entries
is performed on the 28 October 2019. Thereby, we have included all available literature (published
from 1900 onward) in all languages.
1 The Web of Science Core Collection is a curated bibliographic database containing peer-reviewed scholarly journals,
books and conference proceedings published worldwide in the sciences, social sciences, and arts and humanities disciplines.
It is available at http://isiknowledge.com/wos.
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Our systematic review consists of the five steps outlined in Figure 1. The original corpus
of publications is extracted from the Web of Science considering all documents referring to
personalized health or healthcare, with respect to precision, individualized, personalized, stratified
or genetic medicine. Further, we require the results to contain a link to health insurance, payers or
reimbursements.2 To be exhaustive, we include the various spellings of PM as well as words affiliated
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Figure 1. PRISMA review protocol based on Moher et al. (2015).
In the second and third steps of the protocol, we manually scan the titles and abstracts. In the
selection process, we retain literature relevant to one of our themes of interest, i.e., the payment for
PM, the existence of reimbursement strategies, and the implementation of PM into the current health
insurance paradigm. We exclude 298 records that are not in the scope of our review. The assessment
of the eligibility of the full text of the remaining 121 publications yields 94 exclusions. Subsequently,
the fourth and fifth steps consist of backward and forward tracking. In backward tracking, we browse
the bibliography of the 27 retained publications to select citations that are beyond the selection criteria
of our first step but relevant for the review. Regarding forward tracking, we investigate Google Scholar
2 The full query used is as follows: (ALL = “personalized health" OR ALL= “personalized health" OR ALL=
“personalized healthcare" OR ALL= “personalised healthcare" OR ALL= “personalized health care" OR
ALL= “personalised health care" OR ALL= “precision medicine" OR ALL= “individualized medicine" OR
ALL= “individualised medicine" OR ALL= “personalized medicine" OR ALL= “personalised medicine" OR
ALL= “stratified medicine" OR ALL= “genetic medicine" OR ALL= “genomic medicine") AND (ALL = “health
insur*" OR ALL= “payer*" OR ALL =“reimbursement").
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relevant publications that cite one of the retained articles from the third step. In the Appendix A we
summarize the reviewed papers along their focus, the methodology used, and the key contents with
the main provided results.
Throughout the scanning of the literature, we outline three major topics. All relevant literature is
falling into at least one of the following subjects:
1. Economic relevance of PM. Insurers as rational economic agents need proof of the
cost-effectiveness of PM technologies before granting coverage. We include all literature that
provides evidence, economic indicators related to PM, and tools and methods to foster the
building of evidence. This includes but is not restricted to the two major approaches, i.e., contracts
between manufacturers and payers to generate the evidence and standardization of data provision
by assessment bodies.
2. Governance challenges. In this stream we include literature that tackles the heterogeneity
for inter- and intra-countries PM coverage. This includes, for example, papers that highlight
the emerging discrepancies from the existence of a myriad of contracts, the standardization of
reimbursement thresholds, and the need for enhanced communication between stakeholders.
3. Healthcare system implementation. Here, we are interested in all actionable ideas to
overcome the hurdles linked to, for example, technology and pricing, that impede a successful
implementation in current healthcare systems. Insights to overcome these obstacles include, for
example, risk-sharing or evidence development contracts between manufacturers and payers.
The first author handled the selection and scoping of the papers. The second author conducted the
proof-reading to validate the collection. In case of disagreement, both authors discussed and reached a
consensus. Additionally, both authors carried out a synopsis of the reviewed papers by extracting for
each paper the region under study, the methodology used, the key contents and main results as well as
the main topics the paper addresses.
2.2. Synopsis of the Results
Throughout the review that we present in detail in the following sections, we observe several
recurring issues that the institutional payers face when dealing with PM. These challenges cover
three dimensions—economic relevance (see Section 3), governance (Section 4) and implementation
in the healthcare system (Section 5). Put briefly, the available evidence of economic efficiency is
thin, of heterogeneous quality and assessed using too many different ad hoc metrics. This hurdle
impedes or delays coverage and patient access to PM. To overcome this, potential solutions include
manufacturer-payer partnerships and public subsidies to generate evidence, coupled with the
establishment of universal health technology assessment (HTA) methodologies, the harmonization of
guidelines and the economic requirements to address data quality. The second obstacle is the observed
heterogeneity in coverage for PM technologies on various levels, internationally, as well as at the
countries’ scale. This can be attributed to multiple factors, among them a lack of standardization
as highlighted above, the existence of a myriad of payer–manufacturer contracts and the in-place
national healthcare scheme. Possible manners to unify coverage are the centralization of HTA to
exclude discrepancies, clearer communication among stakeholders and the sharing of information
beyond country borders. Finally, an assessment of the characteristics of PM highlights the underlying
difficulties that payers encounter. Among them, we find that gene-based tests and diagnostics are
deemed as experimental or investigational and without a clear actionable outcome. High costs also
often characterize PM technologies along with a difficulty in predicting future expenses. To tackle
this final issue, diverse approaches are possible. While few authors emphasize on the necessity to
move to value-based pricing and coverage, others present numerous means to alleviate the financial
burden of PM (e.g., multiyear contracts, health currency and government interventions). Authors also
expose rather successful examples of PM inclusion in the healthcare system with payer–manufacturer
partnerships such as price–volume agreements, usage caps or pay-for-performance contracts.
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3. Economic Relevance: Lack of Evidence and Efficiency Metrics
3.1. Description of the Challenges
PM is an emerging field and as of today, we do not have enough hindsight about its economic
relevance. The insufficient amount of documentation regarding real-world data, i.e., the cost-effectiveness
of a personalized drug or treatment after its implementation into clinical practice, is highlighted in
the literature. For instance, Terkola et al. (2017) conducted a literature review to identify studies that
confront randomized controlled trial results (performed before the introduction of the drug) with
later-obtained data from clinical practice: they find such studies nonexistent. A large number of
papers they reviewed either emphasize this issue or ask the reader to bear it in mind. Among the
26 papers mentioning economic relevance, more than 60% bring up the lack of studies assessing the
applicability of PM. While some articles simply mention the issue (Degtiar 2017; Amendola et al. 2019),
others blame the paucity of evidence as being one of the hurdles the field must overcome to enable
an optimal coverage (Deverka et al. 2007; Sullivan et al. 2011; Faulkner et al. 2012; Fugel et al. 2012;
Hresko and Haga 2012; Cohen et al. 2013; Terkola et al. 2017). Without clear documentation on the
cost-effectiveness of PM, payers do not have any incentive to reimburse it as it is not proven to make
sense economically. Alongside this uncertainty, payers admit being skeptical regarding the clinical
usefulness of PM drugs and technologies. In the paper by Graf et al. (2013), 50% of the assessed private
payers report the need of evidence for clinical utility. On this topic, we observe a particular focus on
pharmacogenomic/pharmacogenetic tests (PGx) and companion diagnostics (CDx). These tests link
the individual’s genetic variations to drug responses to provide the optimal drug and determine the
appropriate dosage. The same ascertainment is made by Deverka (2009) in an overview of evidence
for PGx. The drug management following the CDx, i.e., the effective use of the right drug at the right
dosage to maximize efficacy, is questioned. Several other authors account for this issue, among them
Deverka et al. (2007), Meckley and Neumann (2010), Sullivan et al. (2011), Hresko and Haga (2012),
Faulkner et al. (2012), Cohen et al. (2013), Merlin et al. (2013), Towse and Garrison (2013),
Cohen and Felix (2014), Terkola et al. (2017), Phillips et al. (2017) and Lu et al. (2018). The unclear
outcome of PGx, CDx testing or more broadly PM, holds payers back from covering such procedures.
There remains a high level of uncertainty about the compliance of the patient or health practitioner to
the results of the CDx or PGx tests and to a more efficient drug use.
Regarding current available evidence, it is rather scarce, heterogeneous in terms of quality
and used metrics, and payers consider it as insufficient to offer coverage. There is no universal
evidentiary standard and authors navigate through cost-utility and cost-effectiveness analysis with
various outputs like, for example, cost per quality-adjusted life years (QALY), cost per life years
gained or incremental cost-effectiveness ratio (Simeonidis et al. 2019). HTA is a process designed to
appraise the value of a drug or technology by asserting its cost-effectiveness, safety, clinical utility,
and, when considered, social aspects. The outcome of the evaluation serves decision-makers regarding
coverage and reimbursement. So far, despite the efforts of several HTA agencies such as the National
Institute for Health and Care Excellence (NICE) in the United Kingdom, the Haute Authorité de Santé
(HAS) in France or the Institute for Quality and Economic Efficiency in Healthcare (IQWiG) in Germany,
no standard framework has been adopted. In a systematic review of pharmacogenetics and genomic
screening programs, Vegter et al. (2008) underlined the absence of standardization in HTA among
the reviewed studies. The Lancet Oncology Commission comes to the same conclusion regarding
cost-effectiveness analysis of PGx and adds that this lack of harmonization hinders reimbursement
(Sullivan et al. 2011). In the following years, authors point out the lack of a clear evidentiary framework
in PM. According to Hall and McCabe (2013), “the standards for establishing evidence on effectiveness
and cost-effectiveness of personalized medicine technologies are considerably less well-defined
than those for conventional health technologies”. In their literature review, Knowles et al. (2017)
reported that 16% of the assessed papers are discussing “conflicting and unclear evidentiary standards
in regulations”. The same observation is made by Miller et al. (2011), Faulkner et al. (2012),
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Fugel et al. (2012), Messner et al. (2016), Knowles et al. (2017) and Simeonidis et al. (2019). When there
is no governmental institution for the HTA, each payer has its cost-effectiveness and clinical utility
standards and without a clear framework for assessing PM, the field presents heterogeneous evidence.
Finally, Meckley and Neumann (2010) conclude their case study on six paired genetic tests and
treatments by understanding that “more generous reimbursement of PM technology likely awaits
more high-quality evidence”, thereby summarizing both obstacles, the quantity of cost-efficiency data
and its quality.
3.2. Discussion of Potential Solutions
We group possible ways to deal with the aforementioned issues in two approaches: top-down
and bottom-up. The top-down approach consists of establishing standards for the HTA at a national
or international level. The bottom-up approach resides in the creation of data through contracts
between payers and manufacturers. Each approach tackles the issue differently. On the one hand,
by standardizing the HTA, manufacturers will present harmonized evidence, which is of equal,
deemed sufficient, quality to be assessed and the product to access the market. Subsequently, the payers
will have access to these data and be able to make a well-informed decision. On the other hand, if the
partnership alternative is favored, the data generated via these contracts will correspond exactly to the
needs of the payer to assess the cost-efficiency or value of a particular drug or technology.
From the reviewed papers, Miller et al. (2011), Garfield (2011), Payne and Annemans (2013),
Vozikis et al. (2016), Lu et al. (2018), Lu et al. (2018) and Simeonidis et al. (2019) agree on the
standardization of HTA to be a valid solution. Be it on an international level (Terkola et al. 2017),
European level for European Union countries (Garfield 2011) or at a national level. They assert that the
benefit of standardization would lie in a harmonized and clear regulation of economic requirements
for the HTA agencies to follow, thus facilitating the assessment process. Knowles et al. (2017) take
a step further and recommend an alignment between regulators and payers on data specification.
Both measures, the standardization of economic requirements and the alignment between stakeholders
will homogenize the requirements and the assessment process to develop a common evidence base.
The United Kingdom is a good example of HTA process standardization where NICE is responsible
for assessing both efficacy and efficiency of a treatment, to subsequently give recommendations for
its administration by the National Health Service (NHS). NICE’s cost-effectiveness threshold ranges
from £20,000 to £30,000 per QALY (McCabe et al. 2008). Only if a drug is below the threshold, it is
recommended for the provision by the NHS. In a comparative assessment of European reimbursement
systems conducted on behalf of the Personalized Medicine Coalition, Garfield (2011) graded ten
countries’ market access for PM technologies. Among the evaluated European countries, the United
Kingdom received the best score in two criteria, the HTA process for diagnostics and the HTA
process for companion products, confirming the straightforward nature of the appraisal process.
Finally, Miller et al. (2011) qualify the United Kingdom’s practices as “perhaps the best developed
technology evaluation and medico-economic assessment system”. The United Kingdom, thus,
illustrates a successful standardization of the HTA process.
Regarding the bottom-up approach, there are several manners to constitute quality real-world
data that are already in place for similar issues touching any drug. Thomas et al. (2010) suggested
that reimbursement systems should foster evidence development. The first method is to find
coverage with evidence development (CED) agreements. CEDs are contracts between a payer
and a manufacturer, where the former commits to providing its members temporary coverage
for an “investigational” or “experimental” drug or technology. In return, the latter must enroll
these members in a payer-approved clinical program destined to generate enough evidence for the
payer to make an informed decision about the continuation of the coverage (Garrison et al. 2013;
Akhmetov and Bubnov 2017; Lu et al. 2018). The use of CEDs permits the generation of real-world
data that are then used to compute the final cost-effectiveness estimate. This type of contract is in
use for “regular” drugs in several countries like Sweden or the Netherlands where, according to
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Ferrario and Kanavos (2015), there were 29 and 52 CEDs, respectively, in 2015. The Netherlands
has been a recurring example of public–private partnerships between payers and manufacturers
(Akhmetov and Bubnov 2017; Faulkner et al. 2016; Ferrario and Kanavos 2015; Garrison et al. 2013).
In both the Netherlands and Sweden, however, these contracts are not used at first instance,
they are introduced after a drug’s inconclusive results of efficacy or high price. In other countries,
these agreements are also expanding. In a survey conducted by Cohen and Felix (2014) among
Medicare payers, 9 out of 11 responded that they would adopt CED contracts to build improved
evidence for CDx. However, even though authors are enthusiastic about the issues this form of
partnership addresses (Chalkidou and Rawlins 2011; Hresko and Haga 2012; Sullivan et al. 2011),
they must be used with caution as CEDs do have several drawbacks. First, it is unclear who
should bear the financial burden of demonstrating the clinical utility. Lu et al. (2018) stated that
the costs would remain with the manufacturer. However, according to Lu et al. (2015) for instance,
the Australian government has funded evidence generation in the past, and manufacturers did not
share the costs. Subsequently, as reported by Garrison et al. (2013), in the United States, drugs on
CED contracts between Medicare and manufacturers have not been de-listed even after being proved
to offer only little advantage with the potential cost of increased risk of mortality. Boon et al. (2015)
make a similar observation in the Netherlands. In a subsample of 46 orphan drugs, none of them
have been de-listed even if showing little evidence of cost-effectiveness. Besides the fact that the
delay for evidence building (four years in the Netherlands for instance) is considered as rather short,
pressure from the public and ethics makes the de-listing on the sole cost-effectiveness criteria difficult.
Finally, Garrison et al. (2013) pointed out the importance of a well-defined contract between the two
parties as both may engage in suboptimal behavior. The conditions regarding the outcomes must
be specified, such as the price discount, if the drug does not meet the target or in case of delay of
data delivery.
Another manner to promote data collection is to resort to public financing. Several authors
emphasize on the role of the government in the provision of healthcare (Vozikis et al. 2016) and hence
its participation in evidence generation. Deverka (2009) and Towse and Garrison (2013) suggested the
participation of the State by subsidies or public investments while Simeonidis et al. (2019) propose that
“State-owned research institutions and universities” work along the private sector.
Finally, a third solution arises through data sharing. Lu et al. (2018) proposed a collaborative
model, which collects and shares all existing health data. Thereby, they envision to use existing data
from electronic health records and merge them with clinical outcomes from genetic interventions and
insurance claims to obtain a comprehensive flow of information. The idea is to get large national
databases containing genotype-phenotype-linked information. Such database would enable the
combination of genetic data through test results and further costs from the usage of these tests through
insurance claims.
Despite the relative novelty of the field, some solutions to current issues are present. The quality
of the evidence of the cost-effectiveness of PM can be tackled by harmonization of HTA processes at an
international scale, whereas specific coverage agreements can promote further evidence generation.
4. Governance: Heterogeneity in Coverage
4.1. Description of the Challenges
PM being in its infancy, policymakers and insurers only slowly adapt their coverage guidelines.
A few papers review the patient reimbursement systems and coverage for PM technologies of European
countries. When comparing reimbursement strategies, Garfield (2011) noted that each country has a
specific HTA and reimbursement process. Because of these disparities, Miller et al. (2011) described the
European HTA system as decentralized, hence less effective, and qualify the market penetration of PM
as “minimal”. In subsequent studies, Fugel et al. (2012) and Payne and Annemans (2013) still observe
substantial differences in coverage among European countries and others in the world (Degtiar 2017).
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On closer inspection, this heterogeneity is present in countries sharing some common
characteristics. For example, Italy and Germany have been mentioned to have discrepancies
in reimbursement and coverage strategies because of their decentralized healthcare systems.
Garfield (2011) presented the example of these specific countries where there is a significant difference
among regions in terms of coverage for PM. The author further exposes that in Europe, reimbursement
and HTA schemes can be made either nationally or regionally whereas regulatory decisions are made
at the largest level, centrally or nationally. This creates delays and eventually inconsistencies in the
coverage and reimbursement within a country. At a finer granularity, this observation is shared for the
United States as well by Deverka (2009), Hresko and Haga (2012) and Lu et al. (2018). The case of the
United States is slightly different because besides the diversity along the states there is another level of
decision-making. Indeed, each payer has its own guidelines and evaluation of PM—which translates
into coverage disparities among public and private stakeholders.
The discrepancies in coverage can be attributed to the heterogeneous regulation. To decide
whether to cover a PM drug or technology, social insurance needs to refer to established guidelines
in addition to having sufficient evidence. Trosman et al. (2010) in their article understand that the
variation in coverage among payers depends on the type of evidence used and the perception of
this evidence. Based on findings from Schwarzer et al. (2015) and Simeonidis et al. (2019), there is
no PM-specific willingess-to-pay (WTP) threshold, i.e., the highest price at which payers are willing
to reimburse a medicine or test. Without such benchmark, each drug is assessed separately and by
different criteria by each HTA institution.
On the country level, another source for disparities in the coverage is that assessment processes
are not standardized. Fugel et al. (2012) added for the case of diagnostics that “there is no clear and
consistent process for value assessment” in Western Europe and in the United States when compared
to what is already in place in the United Kingdom with NICE. Following the results of a policy Delphi
panel, Messner et al. (2016) reported that among 19 overall challenges for the clinical adoption of NGS,
the foremost issue is that “different payers have different evidentiary standards for assessing clinical
utility, leading to inconsistent policies on coverage and reimbursement for NGS-based testing”.
Another reason explaining the existence of such disparities is the myriad of risk-sharing
agreements (RSA, also called managed entry agreements, MEA, or patient access schemes, PAS).
Briefly put, RSAs are contracts between a manufacturer and a payer designed to ease the integration
of a specific drug or technology in clinical practice. The sharing of the risk lies in the payment
amount, which is made dependent either on the clinical outcome, for example, increase in QALYs and
reduction of side-effects, or the economic outcome linked to the cost-effectiveness of the technology.
This outcome, which triggers and defines the price of the treatment, is agreed upon before signing the
contract. This arrangement mitigates the risk taken by the payer on financing a treatment, which has not
strictly proven effective yet (Antonanzas et al. 2019). Further, according to Antonanzas et al. (2019),
another way of splitting risk is for the payer to co-finance additional evidence generation in exchange
of patient treatment access to meet the requirements for cost-efficiency proof. These contracts
can be diverse: some are conditional reimbursements such as CEDs seen previously, others are
price–volume agreements. Different countries have different priorities, for example, the generation
of evidence or accessibility of a drug, resulting in tailored agreements designed to address the
country’s most preoccupying issue and ending up in a puzzle of contracts (Ferrario and Kanavos 2015;
Leopold et al. 2013). For instance, in Australia in 2015, among 98 contracts, some were outcome-based
or financially based, some promoted evidence generation and others were hybrid, depending on the
payer’s priority (Lu et al. 2015). In the context of PM, usual financing through basic social insurance
coverage can represent a challenge. Indeed, it is economically irrational for health insurers and
other healthcare sponsors to cover PM without a clear idea of the clinical or cost-efficiency outcome.
The above-mentioned contracts, hence, offer an alternative that should be seriously considered.
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4.2. Discussion of Potential Solutions
Several authors discuss the variations in the cover for PM technologies and present possible
solutions. For instance, Miller et al. (2011), Fugel et al. (2012) and Lu et al. (2018) pleaded that the
creation of one central HTA agency will reduce differences between payers on the one hand and
foster innovation on the other hand. This centralization of the cost- and clinical-efficiency assessment
will facilitate the drugs’ review and coverage guarantee. The HTA institution would be able to
define a WTP threshold and emit recommendations regarding coverage, thus reducing the number of
stakeholders taking part in the process. Vozikis et al. (2016) add that a single HTA agency could aid
the government to tackle selected priority issues. As discussed in Section 3.2, a valid alternative is also
to go further and standardize regulations regarding assessment and coverage of PM drugs at a larger
leve, for example, international. Nonetheless, as highlighted by Garfield (2011), Schwarzer et al. (2015)
and Faulkner et al. (2016), the extension of a scheme for appraisal and coverage at an international
level is cumbersome. Indeed, each country has its own infrastructure and healthcare system, which
builds on the government’s areas of priority in health management and may not, or hardly fit other
objectives decided at a larger scale.
The need for more transparent communication is also a recurring matter when dealing with
PM, along with an alignment between the conflicting partakers, the manufacturers and payers.
Trosman et al. (2011), Akhmetov and Bubnov (2017), Knowles et al. (2017) and Lu et al. (2018)
advocated that early and enhanced communication improves coverage. Early communication from
the payers to the manufacturers about their requirements for evidence development will improve
decision-making once the payers have the necessary data, reducing the need to create additional
contracts. Further, information sharing among different payers would result in similar assessment
schemes among payers. Thomas et al. (2010) asserted that reimbursement systems should develop
clearer standards. Coupled with communication, collaboration between stakeholders is the next step
for further PM integration. Garfield (2011), in her assessment of European reimbursement systems for
PM, concludes that “greater collaboration [...] should occur between the agencies involved in coverage
and payment”.
5. Implementation in the Healthcare System: Characteristics of Pm
5.1. Description of the Challenges
The first hurdle payers encounter while deciding whether to cover PM is the clinical relevance
of certain procedures. In her review of PM coverage, Degtiar (2017) finds that among private payers,
tests are deemed “experimental” and “investigational”. This observation is recurrent through the
literature, especially for NGS. Indeed, sequencing lies at the frontier between medically necessary
and experimental or investigational technology as its purpose is to simultaneously inspect several
genetic mutations; however, in many cases, without a clear actionable outcome. Additionally,
when another pathogenic mutation is found, unrelated to the primary diagnostic, this so-called
incidental finding can lead to confirmatory testings. The question of whether the following testings
should be reimbursed is another issue payers must think through when deciding for NGS coverage.
Overall, payers encounter difficulties in predicting costs as the presence of a mutation in an individual
makes members of the family eligible for cascade testing, for example in the case of breast cancer
screening (Amendola et al. 2019). This renders the final coverage decision difficult as mentioned by
Trosman et al. (2018) and Trosman et al. (2015). The lack of cost predictability is one of the main
reasons for coverage denial (Deverka and Dreyfus 2014; Messner et al. 2016; Trosman et al. 2010).
In the same vein, Lu et al. (2018) assessed coverage for multigene testing to confirm findings that the
private payers not covering the tests regard them as experimental or investigational. According to
Amendola et al. (2019) and Trosman et al. (2017), germline and hereditary cancer panels suffer from
the same hardship in getting coverage. PM in general suffers from the same pragmatic issue, as seen in
Meckley and Neumann (2010) and Hresko and Haga (2012).
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The second hurdle is the high price of PM technology. By definition, PM drugs are targeted
to small clusters of selected individuals. This spreads the costs of research and development on
a narrower population (Thomas et al. 2010). Further, manufacturers producing drugs aimed at the
treatment of rare diseases have high chances of becoming monopolists on specific markets. Such a setup
typically comes with higher prices (Garrison and Austin 2006; Pauly 2019; Garrison and Towse 2017;
Degtiar 2017). Concrete current examples are orphan drugs (Orofino et al. 2010; O’Sullivan et al. 2013;
Schey et al. 2011). Several authors mention this characteristic of PM technologies as an additional
obstacle to coverage. Degtiar (2017) emphasizes the increase in healthcare costs due to the increase in
the number of orphan drugs on the market. The high price of personalized drugs and their impact
on the total healthcare expenditure in the accounting period (e.g., the year) of the treatment is given.
For PM drugs the time horizon for cost-efficiency studies needs to be different as such drugs often
avoid the longer-term administration of other (cheaper) drugs.
5.2. Discussion of Potential Solutions
As healthcare evolves, the price and valuation of health technologies are to follow. Authors like
Ramsey et al. (2006), Deverka (2009), Deverka and Dreyfus (2014), Carrera and IJzerman (2016) and
Garrison and Towse (2017) mentioned the necessity to switch to a more comprehensive assessment
of the value, the pricing and reimbursement of PM technologies. Kanavos and Angelis (2013),
among others, proposed a framework for a value-based assessment of new medical technologies,
which could easily be applied to PM. They suggest that the so-called multiple criteria decision
analysis (MCDA) should incorporate parameters related to “value creation” complementing the
efficacy and effectiveness criteria of a technology. They have elaborated on an MCDA tree for HTA
that considers 12 criteria along four categories: the burden of illness, the therapeutic impact of the
drug (which incorporates the efficacy and effectiveness parameters), the innovation level and the
socioeconomic impact. Subsequently, weights are assigned to each criterion to compute scores for each
option. This framework could be used to decide either for coverage or for price setting.
In view of the high prices at which the personalization of healthcare comes, it is necessary to seek
the best financing schemes. The coverage of a drug, which could eradicate a health condition can
be seen as an investment decision by the payer. However, under the current healthcare frameworks,
the payer can sometimes not entirely capture the “benefits" of such investments in the following years
(e.g., because the patient receiving the treatment quits the contract with the private insurer that has
paid). A paper by Mattke et al. (2017) classifies multiple solutions to the issue insurers encounter when
deciding to cover an expensive drug. Some could be applied to the case of PM. The authors propose
multiyear contracts with possible compulsory applications in the case of gene therapies. A multiyear
contract would bind the patient to the insurer that funded the cure. This enables the insurer to get
the return of its investment in the following years, as benefits of a cure typically take longer than
a year to emerge. In the same vein, a “health currency” is proposed as a monetization of health
(initially presented by Basu 2015). The idea is that every investment in cures by public or private
payers gives birth to “HealthCoins” that are transferable. When a patient later enrolls in a new health
plan, the new insurer must buy out the health coins from the former payers. Thus, the insurer that
invested in the cure will get partial reimbursement. This currency, hence, decreases the risk borne
by the insurer. Other options include a cure fund or reinsurance for specific high-cost cures. Finally,
the authors discuss government interventions such as patent buyout—where the manufacturer will
be compensated for its investments in innovation, or tax coverage—where the expensive drugs and
technologies can be directly funded through tax revenues.
To reduce the financial risk borne by the payer, RSA (or so-called MEA or PAS) are being
implemented. These contracts can serve several aims simultaneously, such as reducing the risk of outcome
uncertainty, with the example of CEDs (cf. Section 3.2), and granting patient access for high-priced
drugs (Ferrario and Kanavos 2015; Lu et al. 2015; Faulkner et al. 2016; Akhmetov and Bubnov 2017;
Degtiar 2017; Lu et al. 2018). In Figure 2, based on the payer engagement strategies presented
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by Akhmetov and Bubnov (2017, Fig. 1), we lay out the schemes that primarily address the high














Figure 2. Examples of managed entry agreement (MEA) schemes for cost mitigation based on
Akhmetov and Bubnov (2017).
Price-volume agreements (PVA) define a threshold of total expenditure and when the predefined
amount is topped a discount is triggered. These agreements fix prices at a maximum level for a
specific volume (Ferrario and Kanavos 2015). Faulkner et al. (2016) presented the cases of France and
Germany where this type of contract is implemented for high-cost medicine. Similar to PVAs, caps set
a maximum time or dose amount for the treatment to be efficient, above which the manufacturer
pays for additional treatment continuation. These agreements are currently used in the United
Kingdom (and more specifically in England, see Garrison et al. 2013, and Faulkner et al. 2016).
Other solely price-based agreements between the manufacturer and payer, also in place in the
United Kingdom, are rebates or discounts (Ferrario and Kanavos 2015). These agreements are purely
economic and do not contain any outcome component. Another possibility for an institution to
reduce the budget impact by high-priced drugs are traditional co-payment or cost-sharing procedures
(Degtiar 2017; Garrison et al. 2013; Pauly 2019). Under this setting, the patient financially contributes
to the costs for treatments, reducing the payer’s participation (Faulkner et al. 2016). Finally,
the presented pay-for-performance scheme in Figure 2 allows for payers to pay the manufacturer only
in the case of success. This success is designated by both parties as the achievement of an agreed
outcome, which may be a positive health outcome or simply a limitation of negative events (Akhmetov
and Bubnov 2017; Faulkner et al. 2016).
Some of the above arrangements are already in place for non-PM technologies (Garrison et al. 2013;
Ferrario and Kanavos 2015; Lu et al. 2015; Faulkner et al. 2016). Such methods could be successfully
applied to PM to address the raised issues. Some of these contracts can be combined to address
multiple barriers simultaneously, as seen, for example, in Australia (see Lu et al. 2015).
Finally, other types of cost-retaining strategies can be applied. Leopold et al. (2013) reported the
case of trastuzumab, a personalized drug for HER-2 positive breast cancer patients, in Latvia. While the
diagnostic test is reimbursed for all breast cancer patients, the treatment is subject to assessment. Due to
a limited budget, the reimbursement of the treatment is analyzed on a case-by-case study, thus reducing
expenses to only positive and deemed necessary cases. In the latter procedure, other non-economic
questions arise, notably the decision on “necessity” in each case relating to ethical issues and the
valuation of QALYs.
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6. Concluding Discussion
In our review of the PM literature and our assessment of the building blocks of PM from a payer’s
perspective, we reveal three major impediments for integrating PM in healthcare systems. The hardship
comes from different areas: economic relevance, governance and practical implementation of PM in the
healthcare system. Solutions are available but need to be properly put into practice. A common
approach lies in the collaboration among partakers. Collaboration between manufacturers and
institutional payers like a national social health insurance scheme or a private insurer will more easily
and rapidly generate the necessary base of evidence for drug coverage. Cross-border collaborations
between HTA agencies and payers would help achieve standard thresholds for the coverage of
treatments. Finally, a close collaboration among the various payers themselves is necessary to provide
unified coverage by sharing and harmonizing data.
In the building of the new paradigm, the implication of each stakeholder is necessary to ensure
the financial management of PM. In particular, the payers and manufacturers are the enablers of the
next phase of evolution toward an individualized medicine. On the one hand, payers are asked to
take a leap of faith in contributing to evidence generation by covering PM drugs blindfolded on its
real-world cost-efficiency. To secure the jump, manufacturers, governments and HTA bodies must
establish guidelines and a standard procedure for PM technologies to be quickly assessed. On the
other hand, the appraisal of coverage based on the calculation of pure economic costs should include
the value created, for example, in terms of QALYs, by the use of personalized treatments. Finally,
with the new outlook on healthcare, and especially with the necessity to at first invest in a system that
may not yet be proven economically rational, health should be regarded as an investment in the long
term rather than a cost in the short term.
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Table A1. Synopsis of reviewed papers.





– Manufacturers may benefit from accessing claims data
– Collaboration and trust are key, data exchange improves evidence paucity




US Review of coverage
(N = 31)
– Guidelines not meaningfully identify patients who may benefit from testing
– Germline cancer test often deemed experimental or not medically necessary
– Difference in denial because of difference in evidence assessment
X X
Basu (2015) Conceptual article – HealthCoins to address the “free-rider” problem among insurers
– HealthCoins to enable smooth investments across insurers
– HealthCoins are produced with investments and bought out by next insurer
X
Boon et al. (2015) NL Discussion – None of 46 orphan drugs on conditional reimbursement were de-listed
– De-listing solely on cost-effectiveness faces social pressure




Discussion – PM drugs are particularly costly due to narrower customer base
– Stakeholders have different WTP thresholds per QALY




Discussion & case studies – Discussion of interrelated impact between CED and pharmacogenetics
– CED contracts offer an alternative solution for public reimbursement






(N = 8 PGx)
– Lack of comprehensive reimbursement of CDx and high costs of PGx
– Often low evidence of clinical usefulness




US Review (10 drug-
diagnostics) and survey
(N = 11)
– Variable and relatively high patient co-insurance
– Drug reimbursement is not necessarily coupled with diagnostic coverage
– Need to increase the body of evidence; CED to increase data
X
Degtiar (2017) 42 countries Literature review
(N = 69 articles)
– Private payers deem tests investigational and cover them less
– Value-based assessment for reimbursement to incorporate other criteria






– Lack of clinical utility as a barrier for molecular medicine coverage
– Public–private partnership for effectiveness research data generation
– Establishment of accurate regulation to avoid uncertainty
X
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Table A1. Cont.
Reference Region Methodology Key Contents and Main Results ER GC HS
Deverka and
Dreyfus (2014)
Review of NGS coverage – Lack of clinical utility information and standards
– Move reimbursement from a cost-based to a value-based approach
– Payers concerned with reimbursement of confirmation of incidental findings
X
Deverka (2009) Commentary – Payers have evidence requirements more rigorous than regulators
– Coverage assessment needs positive net benefit as compared to usual care




US Review – Research prioritization and early standardized value assessment
– Best practice for clinical evidence development/health economic assessment




EU & US Review of pricing and
reimbursement
– Earlier cross-stakeholder engagement and regulatory tools
– Flexible and adaptive payer approaches to pricing and reimbursement








– Conceptual framework for MEA agreements and tests
– Different types of agreement and medicine-indications across countries
– Variation from governance and risk-perception
X X X
Fugel et al. (2012) EU & US Review of pricing and
reimbursement
– Lack of a consistent process for value assessment of more complex diagnostics
– More flexible pricing and reimbursement systems are needed
– Further development of framework for access of diagnostic-based therapies
X X




– European reimbursement systems are not appropriately aligned
– Change health technology assessment methodologies




Commentary – Limitations of genetic prediction and lack of economic incentives slows PM
– Clinical successes often on a case-by-case basis




Concepts for pricing and
reimbursement
– Take an economic perspective and a broader concept of value
– Valuations beyond QALY including changing preferences over life






– Performance-based risk-sharing arrangements to reduce uncertainty
– Practical recommendations for state-of-the-art methods
– Data regulation and long-run societal perspective needed
X X
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Reference Region Methodology Key Contents and Main Results ER GC HS
Graf et al. (2013) US Review of coverage
(N = 206 policies)
– Half of insurers do not cover specific genetic-related services
– One-third of the insurers addressed genetic testing




Commentary – Cost-effectiveness standards are more poorly defined for PM
– Regulation of diagnostic tests less rigorous




US Review of coverage
(N = 41 policies)
– Lack of evidence of clinical utility as a barrier for coverage
– Variable coverage determinations and factors considered






– Multiple criteria decision analysis: HTA for broader value inclusion
– Values: illness burden, innovation, therapeutic and socioeconomic impact





(N = 344 articles)
– Science of PM requires broadening beyond genetics
– Lack of clinical uptake due to structural and human factors






Survey (N = 27) – In the EU four broad models for PM funding (case study trastuzumab)
– Most EU countries: combined hospital and 3rd party payer strategy
– No combined funding for diagnostic test and medical treatment
X X
Lu et al. (2018) US Review of coverage
(N = 18 payers)
– Important variation among guidelines, especially in private payers
– A second HTA agency assessment could reduce coverage variation
– Increased dialogue and sharing prior information to reduce coverage variation
X X X
Lu et al. (2015) Asia-Pacific
countries
Literature review – Most PAS focus on pharmaceuticals, few on medical technologies
– Majority involve pricing arrangements, evidence generation rarely used
– Australia has strong experience with PAS
X X X
Lu et al. (2018) Commentary – Clinical utility unanswered for many genomic technologies
– Propose building blocks for rapid generation of evidence




Discussion – Policy options to remedy the “free-rider" problem with high-cost cures
– Incentives for patients, coordination among payers, government intervention
– Collaborations for equitable mechanisms for cost-benefits distribution
X
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Reference Region Methodology Key Contents and Main Results ER GC HS
McCabe et al.
(2008)
UK Commentary – NICE is the only entity to assesses effectiveness and cost-effectiveness
– Cost-effectiveness threshold of NICE is £20,000 per QALY




US Case studies of
diagnostics and
treatments (N = 6)
– Strength of evidence is the strongest predictor for drug reimbursement
– Regulatory oversight and cost-effectiveness not associated to reimbursement






– Safety, effectiveness, and cost-effectiveness for reimbursement decisions
– Linkage of different types of evidence and likely clinical benefits of drugs




US Policy Delphi panel
(N = 48)
– Proprietary variant databases are a key challenge for NGS coverage
– Payer policies and perceived inconsistency in standards as a barrier
– FDA regulation not strongly perceived as a barrier
X X X
Miller et al. (2011) EU Market study – Insufficient clarity on reimbursement and regulatory pathways for PM tests
– Value-based public sector pricing required in Europe
– EU market suffers from decentralization
X X
Pauly (2019) Review of coverage – Study on patterns of insurance coverage for PM and efficiency
– Heterogeneity in marginal benefits call for partial coverage




EU Literature review – Successful market access driven by generation of robust evidence
– Take account of the different stakeholders’ perspectives




US Review of coverage
(N = 55 policies)
– Multigene tests do not fit standard coverage framework
– High degree of variability in coverage assessment for multigene tests




Commentary – Currently, reimbursement is based on the price rather than clinical value
– Reimbursement to move to an evidence- and value-based paradigm




11 countries Review of thresholds – Explicit cost-effectiveness thresholds only in two countries (UK and TH)
– Implicit values in other countries and different decision-making rules
– No PM-specific threshold found
X
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Table A1. Cont.




(N = 96 articles)
– Outcome of interventions mostly measured in QALYs
– Total cost estimated upon direct medical cost data






Review of cancer care
delivery
– Clinicians require analytic and clinical validity before testing
– Coverage with evidence development is an opportunity to generate data




Commentary – Lack of real-world data regarding costs and health outcomes
– No study confronting clinical trial and real-world data




US Industry perspective – Need for reimbursement that fosters evidence development
– Reimbursement systems should develop clearer standards




Commentary – Collaboration between stakeholders needed to increase evidence creation
– CED for realistic expectations for evidence standards




US Interviews (N = 7) – Heterogeneity in clinical evidence perception among payers
– Clinical effectiveness is a paramount factor in coverage decision for all payers




US Literature review and
interviews (N = 11)
– Payers use HTA more extensively for PM than for other technologies
– Limited relevance if HTA unavailable and insufficient nonclinical factors




US Interviews (N = 24
experts / payers)
– Next-generation tumor sequencing deemed experimental/investigational
– Efforts for evidence generation and incorporation into policies necessary




US Interviews (N = 11
payers)
– Adjustment needed for PM to fit the coverage framework
– All interviewees find that lack of evidence is a coverage barrier




US Review of coverage – Three approaches to adapt coverage framework for tumor sequencing
– RSA with manufacturer for performance data; CED for evidence generation
– Technology-specific coverage based on number of genes
X
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Table A1. Cont.
Reference Region Methodology Key Contents and Main Results ER GC HS
Vegter et al. (2008) Literature review
(N = 20 articles)
– Level of consistency among economic analyses generally poor
– Extensive sensitivity analyses and incorporate evidence-based data




EU Review of pricing and
reimbursement
– Overview of basic principles guiding governance of genomic testing services
– Need for one single HTA agency for selection of priority areas
– Merge all the current reimbursement processes under one committee
X X
Note: ER = Economic relevance, GC = Governance challenges, HS = Implementation in the health care system.
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